Meta-analysis finds SGLT2 inhibitors reduce cardiac arrest risk in CKD patients
SGLT2 Inhibitors Lower Cardiac Arrest Risk in Kidney Disease
This meta-analysis of 8 RCTs evaluated SGLT2 inhibitors versus placebo in patients with chronic kidney disease. SGLT2i significantly reduced…
A meta-analysis of 8 trials found SGLT2 inhibitors cut cardiac arrest risk by 47% in chronic kidney disease patients, though other arrhythmi…
Qiliqiangxin reduces cardiovascular events in heart failure with reduced ejection fraction across LVEF subgroups
Lower heart function gets worse care but this drug helps everyone equally
This post hoc analysis of a Phase 3 RCT in 3110 patients with symptomatic HFrEF found that adding qiliqiangxin to guideline-directed therapy…
This heart drug works for patients with weak hearts just as well as it does for those with slightly stronger pumps